Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial

Background: Liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while simultaneously improving the targeting of the drug to the primary tumor and to metastases by increasing circulation time in the body fluids and tissues. The primary objectives were to de...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Michalopoulou, P., Bastas, A., Marosis, K., Stathopoulos, J., Provata, A., Yiamboudakis, P., Veldekis, D., Lolis, N., Georgatou, N., Toubis, M., Pappas, Ch., Tsoukalas, G.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962260/
https://www.ncbi.nlm.nih.gov/pubmed/20439345
http://dx.doi.org/10.1093/annonc/mdq234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962260/
https://www.ncbi.nlm.nih.gov/pubmed/20439345
http://dx.doi.org/10.1093/annonc/mdq234

Ejemplares similares